Literature DB >> 24831034

Clinical and prognostic value of elevated CA125 levels in patients with coronary heart disease.

X Rong1, Z Yunke, L Guoping, C Zhenyue.   

Abstract

OBJECTIVE: The aims of this study were to explore the association between serum level of carbohydrate antigen 125 (CA125) and coronary heart disease (CHD), and to evaluate its role in the short-term prognosis of CHD patients.
METHODS: A total of 150 patients were enrolled in the study and divided into an acute coronary syndrome (ACS) group (n=40), a stable CHD group (n=64), and a control group (n=46) according to clinical presentation and angiographic results. Fasting blood samples were collected at two time points, on admission and on the fifth day after hospitalization for the measurement of serum CA125 and other biomarkers.
RESULTS: Serum CA125 levels in both CHD subgroups were significantly higher than the control group on admission (p < 0.01 for the ACS group and p < 0.05 for the stable CHD group). The differences remained significant on the fifth day after hospitalization (both p < 0.05), and the CA125 levels in the ACS group were higher than in the stable CHD group on the fifth day (p < 0.05). The CA125 levels were positively correlated with pro-brain natriuretic peptide (pro-BNP), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), and negatively correlated with left ventricular ejection fraction (LVEF). Compared with the other patients, serum CA125 levels on admission were significantly elevated in the patients who suffered from heart failure events during a 3-month follow-up (p = 0.037). The CA125 level on the fifth day of hospitalization in these patients stayed at a significantly higher level than the other patients (p = 0.002).
CONCLUSIONS: The serum CA125 levels were significantly related with cardiac function in CHD patients. Serum CA125 levels that remain elevated after CHD onset could be helpful for predicting the short-term risk of heart failure events in CHD patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24831034     DOI: 10.1007/s00059-014-4109-y

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  20 in total

1.  N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes.

Authors:  Torbjørn Omland; Anita Persson; Leong Ng; Russel O'Brien; Thomas Karlsson; Johan Herlitz; Marianne Hartford; Kenneth Caidahl
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

Review 2.  CA 125 in ovarian cancer.

Authors:  M E van der Burg; F B Lammes; J Verweij
Journal:  Neth J Med       Date:  1992-02       Impact factor: 1.422

3.  Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.

Authors:  Serge Masson; Roberto Latini; Inder S Anand; Tarcisio Vago; Laura Angelici; Simona Barlera; Emil D Missov; Aldo Clerico; Gianni Tognoni; Jay N Cohn
Journal:  Clin Chem       Date:  2006-06-15       Impact factor: 8.327

4.  Incidence of normal values of natriuretic peptides in patients with chronic heart failure and impact on survival: a direct comparison of N-terminal atrial natriuretic peptide, N-terminal brain natriuretic peptide and brain natriuretic peptide.

Authors:  Martin Hülsmann; Rudolf Berger; Deddo Mörtl; Odette Gore; Brigitte Meyer; Richard Pacher
Journal:  Eur J Heart Fail       Date:  2005-06       Impact factor: 15.534

5.  CA 125 and its relation to cardiac function.

Authors:  H Nägele; M Bahlo; R Klapdor; D Schaeperkoetter; W Rödiger
Journal:  Am Heart J       Date:  1999-06       Impact factor: 4.749

6.  Clinical and prognostic value of elevated CA125 levels in patients with congestive heart failure.

Authors:  Nikos T Kouris; Dimitra D Kontogianni; Eftihia P Papoulia; Georgia S Goranitou; Ioannis D Zaharos; Haris A Grassos; Eleni M Kalkandi; Maria D Sifaki; Dimitris K Babalis
Journal:  Hellenic J Cardiol       Date:  2006 Sep-Oct

7.  The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters.

Authors:  Nikos T Kouris; Ioannis D Zacharos; Dimitra D Kontogianni; Georgia S Goranitou; Maria D Sifaki; Haris E Grassos; Eleni M Kalkandi; Dimitris K Babalis
Journal:  Eur J Heart Fail       Date:  2005-03-02       Impact factor: 15.534

8.  Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure?

Authors:  Julio Núñez; Eduardo Núñez; Luciano Consuegra; Juan Sanchis; Vicent Bodí; Angel Martínez-Brotons; Vicente Bertomeu-González; Rocio Robles; Maria J Bosch; Lorenzo Fácila; Helene Darmofal; Angel Llàcer
Journal:  Heart       Date:  2006-12-12       Impact factor: 5.994

9.  Serum levels of different tumour markers in patients with chronic heart failure.

Authors:  Pompilio Faggiano; Antonio D'Aloia; Loretta Brentana; Tommaso Bignotti; Claudia Fiorina; Enrico Vizzardi; Livio Dei Cas
Journal:  Eur J Heart Fail       Date:  2005-01       Impact factor: 15.534

10.  Usefulness of serum CA125 measurement for monitoring pericardial effusion.

Authors:  T Seo; Y Ikeda; H Onaka; T Hayashi; K Kawaguchi; C Kotake; T Toda; K Kobayashi
Journal:  Jpn Circ J       Date:  1993-06
View more
  3 in total

1.  Plasma carbohydrate antigen-125 for prediction of atrial fibrillation recurrence after radiofrequency catheter ablation.

Authors:  Qingya Wang; Chengjing Dang; Haoyu Liu; Jie Hui
Journal:  BMC Cardiovasc Disord       Date:  2021-08-19       Impact factor: 2.298

2.  Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients.

Authors:  Ahmad Separham; Mohsen Abbasnezhad; Golnesa Shahnazarli; Alireza Khoshbahar
Journal:  J Cardiovasc Thorac Res       Date:  2018-05-21

3.  Serum Tumor Marker Carbohydrate Antigen 125 Levels and Carotid Atherosclerosis in Patients with Coronary Artery Disease.

Authors:  Guo-Yao Sang; Zhao-Yun Chen; Cun-Ren Meng; Tian Tian; Zhao-Xia Zhang
Journal:  Open Med (Wars)       Date:  2018-12-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.